Theranica develops a patch for migraine treatment

21 September, 2016

The Patch is based on advanced wireless neuromodulation thechnology for relive of migraine pain. The patch is connected to an app giving the patient control of the treatment

Share via Whatsapp

The Patch is based on advanced wireless neuromodulation thechnology for relive of migraine pain. The patch is connected to an app giving the patient control of the treatment

theranica-painTheranica Bio-Electronics,  newly established medical device startup offering a ‘smart’ patch that delivers neuromodulation therapy for migraine treatment, announced the closing of its seed financing round from a group of top angel investors, led by the renowned entrepreneur and investor Dr. Shimon Eckhouse. Eckhouse will be serving as Chairman of the company. The company has not disclosed the amound of capital raised in the seed round.

The company’s first product, Nerivio Migra, addresses the widespread problem of migraine headaches by providing neuromodulation therapy through a non-invasive, wearable, and disposable ‘smart’ patch. The product can be used at the onset of a migraine attack to provide rapid and significant pain relief, often times completely eliminating all pain.

“We are in the midst of a paradigm shift in the medical world where patients are increasingly seeking non-pharmaceutical solutions to their diseases, especially those that can be applied at home without disrupting their daily routines,” says Dr. Eckhouse. “Leading pharmaceutical companies are responding to this trend as more R&D investment is dedicated to patient-friendly medical devices that complement their existing drug offering. Theranica is perfectly positioned to address this large unmet need through its proprietary wearable technology.”

Recently, the company has expanded its Medical Advisory Board to include two additional neurologists, Dr. Stephen Silberstein and Dr. Charles Argoff. Dr. Silberstein is Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University as well as the former president of the American Headache Society. Dr. Argoff is Professor of Neurology at the Albany Medical College, Director of the Comprehensive Pain Center at the Albany Medical Center, President of the American Academy of Pain Medicine Foundation, and Co-Editor of the Neuropathic Pain Section of Pain Medicine.

“Today, the most common remedy for migraine headaches is medication,” says Dr. Silberstein. “Often the more effective the medication, the more significant the potential side effects, which is why many medications are not recommended for certain patient segments, such as children and pregnant women. Theranica’s solution is safe, easy to use, and shows promising initial clinical results. It has the potential to dramatically change the way patients manage their migraines by allowing them to take back control of their daily routines.”

Posted in: Business , Medical